20 Jul Laverock Therapeutics
David Venables, Ph.D., CEO
Oct. 12 | 11:00am | Rentschler ATMP Ballroom
Stevenage, Herefordshire, UK
Laverock Therapeutics is developing the next generation of programmable allogeneic cell therapies though our novel miRNA platform (GEiGS). Gene Editing induced Gene Silencing (GEiGS) utilizes the cells’ own endogenous miRNA expression profiles and redirects them to knock down target genes of choice, generating silencing in a stable, consistent, tunable and programmable manner in response to the stage of cell development, activation, or its’ in vivo disease related environment.